We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126.
- Authors
West, Howard L; Franklin, Wilbur A; McCoy, Jason; Gumerlock, Paul H; Vance, Ralph; Lau, Derick H M; Chansky, Kari; Crowley, John J; Gandara, David R
- Abstract
Advanced bronchioloalveolar carcinoma (BAC) is a distinct subtype of non-small-cell lung cancer (NSCLC) for which there is currently no optimal therapy. Based on preclinical and clinical data suggesting relevance of the epidermal growth factor receptor (EGFR) axis in BAC, the Southwest Oncology Group initiated a phase II trial (S0126) to evaluate the EGFR tyrosine kinase inhibitor gefitinib in chemotherapy-naïve and chemotherapy-pretreated patients with advanced BAC.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Vol 24, Issue 12, p1807
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2005.04.9890